#healthandmedicine #hormonetherapy #urology #metastasis #prostatecancer #cancerpatients #prostate #radiationtherapy #chemotherapy #cancer #cancerresearch #metastasisdirectedtherapy #androgendeprivationtherapy #sexualdysfunction #surgery #sexhormone
For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) can slow the time to cancer progression, reports a study in The Journal of Urology®. MDT focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT). Metastasis-directed treatment has emerged as a potential alternative for men with "oligorecurrent" prostate cancer - a state of disease with a limited number of metastatic lesions after initial treatment. In the MDT approach, surgery or radiation therapy is used to specifically target the area of cancer spread.
That's in contrast to ADT, systemic therapy to block testosterone and other male sex hormones, which promote the growth of prostate cancer. Androgen deprivation therapy with or without other systemic therapy is the standard treatment for metastatic prostate cancer, but has numerous adverse effects that can decrease quality of life – including sexual dysfunction, bone thinning, and loss of muscle strength, among others. If MDT is effective in controlling limited recurrences, it may avoid or delay the need for ADT.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Website: [ Ссылка ]
